secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000010795-24-000044
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD to acquire Edwards Lifesciences' Critical Care for $4.2B in cash
-------------------------------------------------------------------

- Acquisition price of $4.2B in cash; expected to close by end of calendar 2024, subject to regulatory approvals.
- Critical Care generated >$900M revenue in 2023; BD expects 6-7% growth, >60% adjusted gross margin, >25% adjusted operating margin.
- Funded with ~$1B cash and ~$3.2B new debt; net leverage ~3x at close, targeting 2.5x within 12-18 months via free cash flow.
- Transaction immediately accretive to BD revenue growth, adjusted gross/operating margins, and adjusted EPS.
- Critical Care to operate as separate business unit within BD Medical, led by Katie Szyman, based in Irvine, CA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000044/0000010795-24-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000044/bdx-20240603.htm
  HTML page:      https://secwatch.observer/filing/0000010795-24-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer